MING-CHU CHANGYU-TING CHANGJAU-MIN WONGWEI-SHIUNG YANGTA-CHEN SUCHI-LING CHENPO-CHIN LIANGSHU-CHEN WEIYU-WEN TIEN2020-02-202020-02-2020070885-3177https://www.scopus.com/inward/record.uri?eid=2-s2.0-34250705328&doi=10.1097%2fMPA.0b013e3180547709&partnerID=40&md5=252e717ccd94738088444b2e49eadb34https://scholars.lib.ntu.edu.tw/handle/123456789/461892Objectives: Serum adiponectin (ADP) levels are reported inversely related to the risk in breast, endometrial cancer, and gastric cancer. Serum ADP as a potential marker compared with CA-19-9 in pancreatic carcinoma (PC) and chronic pancreatitis (CP) was studied. Adiponectin and CA-19-9 levels were examined at the time of diagnosis in patients with CP and PC. METHODS: Serum ADP and CA-19-9 levels were measured by immunoassays in 72 patients with PC and 39 with CP and 290 control subjects. RESULTS: The median levels of ADP for PC were significantly higher than those for CP and control subjects (P = 0.0035). Increasing the upper reference value of ADP allowed for better discrimination between CP and PC. The introduction of 28 ng/mL as a cutoff for ADP significantly improved its specificity. At an elevated cutoff level for ADP (28 ng/mL), a better discrimination between PC and CP was obtained. CONCLUSIONS: Adiponectin might be useful in the differential diagnosis of PC and CP with elevated CA-19-9. This gives rise to the possibility that ADP has a potential role in differentiating CP and PC. ? 2007 Lippincott Williams & Wilkins, Inc.[SDGs]SDG3CA 19-9 antigen; fibronectin; adult; aged; article; cancer diagnosis; cancer patient; chronic pancreatitis; controlled study; diagnostic accuracy; differential diagnosis; female; human; immunoassay; major clinical study; male; pancreas cancer; priority journal; protein blood level; reference value; sensitivity and specificityjournal article10.1097/MPA.0b013e3180547709175755402-s2.0-34250705328